ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DVAX Dynavax Technologies Corp

11.01
-0.16 (-1.43%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Dynavax Technologies Corp NASDAQ:DVAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.16 -1.43% 11.01 11.16 11.40 11.26 11.03 11.11 1,876,263 00:40:21

Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference

01/03/2021 9:15pm

PR Newswire (US)


Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Dynavax Technologies Charts.

EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference being held March 9-10, 2021.

(PRNewsfoto/Dynavax Technologies)

The on demand presentation will be available, beginning Tuesday, March 9, 2021 at 7:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-2021-global-life-sciences-conference-301237827.html

SOURCE Dynavax Technologies

Copyright 2021 PR Newswire

1 Year Dynavax Technologies Chart

1 Year Dynavax Technologies Chart

1 Month Dynavax Technologies Chart

1 Month Dynavax Technologies Chart

Your Recent History

Delayed Upgrade Clock